Repatha Cost in 2026: Real Prices & How to Save

Your cardiologist wrote the prescription, the specialty pharmacy called back, and the number they quoted was somewhere north of $700 for a one-month supply. For a drug you may take for the rest of your life.

The Repatha cost picture changed a lot between late 2025 and now, and most of the pages you'll find still quote the old numbers. Here's what two 140 mg pens actually cost in August 2026, why your dosing schedule can swing your annual bill by thousands of dollars, and which cash routes are genuinely cheaper.

How much does Repatha cost without insurance in 2026?

There is no single Repatha price, which is exactly why this is confusing. What you pay depends on where you fill it and which purchasing channel you use.

Repatha is a brand-only biologic made by Amgen. Its US list price has sat above $500 a month since launch, and pharmacy retail — list price plus the pharmacy's markup — pushes it higher. Here's where the actual numbers landed as of August 2026:

Where you buy it	Price for a 1-month supply (two 140 mg pens)	Annual cost
US retail pharmacy (average cash)	About $688	About $8,250
Higher-end US retail quotes	Up to $780	About $9,360
Amgen list price benchmark	About $626	About $7,510
Amgen direct-to-patient (AmgenNow / TrumpRx)	$239	$2,868
CanAmerica Plus cash-pay listing	$710.99	About $8,530

That last row deserves a note, because it runs against what you might expect from a cash-pay network. For most brand-name drugs, sourcing through licensed international pharmacies beats US retail by a wide margin. Repatha in 2026 is the exception: Amgen's own direct-to-patient price is currently the cheapest legitimate cash route in the country. We'd rather tell you that than pretend otherwise.

Prices move. Check the current figure on the Repatha product page before you assume either direction.

Why your dose changes the math more than your pharmacy does

This is the part almost nobody explains, and it's worth more than any coupon.

Repatha comes in one strength for adults: 140 mg per pen. There are two approved dosing schedules, and they don't use the same amount of drug per year.

• 140 mg every 2 weeks — 26 pens per year (about 2.2 pens a month)
• 420 mg once a month — three pens per dose, 36 pens per year

Same medication, same LDL effect, roughly 38% more product. At an average US retail price of about $344 per pen, that's the difference between roughly $8,950 and $12,400 a year. Even at the $239 direct-pay tier, confirm what that price covers — a monthly quote built around two pens doesn't automatically cover a three-pen dose.

If you're on the 420 mg monthly schedule purely for convenience, that convenience has a price tag. Ask your prescriber whether the every-two-weeks schedule is clinically equivalent for you. For most adults on Repatha for LDL lowering, it is.

The $239 direct-to-patient price: what it is and what to check

In October 2025, Amgen launched AmgenNow, a program that sells Repatha straight to patients at $239 a month — nearly 60% below the US list price. The company said it was the lowest Repatha price among G-7 countries and offered it exclusively to US patients first. Amgen also made it accessible through the TrumpRx site, where it's listed at $239.00 against an original price of $625.89.

A few details that matter more than the headline number:

It's open to almost everyone. Uninsured patients, people in high-deductible plans, and anyone who simply prefers to pay cash can use it. Unlike most manufacturer pricing, it's also available to people enrolled in Medicare and Medicaid.

No prior authorization, no step therapy. Patients who buy through the program aren't subject to the insurer requirements that normally gate PCSK9 inhibitors — the paperwork that often forces you to fail on two statins first.

You're paying entirely out of pocket. Money spent here doesn't run through your insurance, so it generally won't count toward your deductible or out-of-pocket maximum. If you're already close to hitting your max for the year, running the prescription through your plan may cost less overall.

The timing wasn't accidental. Amgen announced the program the same week it reported results from VESALIUS-CV, a Phase 3 trial showing Repatha cut major adverse cardiovascular events in people who had never had a heart attack or stroke. A broader eligible population plus a lower price is a volume strategy, and patients happen to benefit from it.

Repatha cost with insurance and on Medicare

If you have commercial coverage, Repatha usually sits on a specialty tier. Your share depends on your deductible, your coinsurance percentage, and whether your plan requires prior authorization — which most do.

On Medicare Part D, roughly three-quarters of Repatha prescriptions cost the patient about $50 or less per month, according to figures cited by the manufacturer. Since 2025, Part D also caps annual out-of-pocket drug spending, which changed the math considerably for people who used to fall into the coverage gap. If you're on Part D, run Repatha through Medicare's Plan Finder before assuming a cash program is cheaper — for many enrollees it isn't.

Medicaid covers Repatha in most states, generally with prior authorization and clinical criteria, and copays are usually $10 or less.

Repatha vs. other cholesterol medications: a cash-price comparison

The honest question underneath "how much does Repatha cost" is usually "is there something cheaper that would still work." Sometimes there is. Here's how the LDL-lowering options compare on cash price as of August 2026.

Medication	Type	Typical US cash cost	Roughly how much it lowers LDL
Repatha (evolocumab)	PCSK9 inhibitor injection	$239–$780/month	55–60%
Praluent (alirocumab)	PCSK9 inhibitor injection	About $490–$690/month	45–60%
Leqvio (inclisiran)	siRNA injection, twice yearly	About $6,500/year	45–50%
Nexletol (bempedoic acid)	Oral, non-statin	$520–$595/month	15–20%
Zetia / generic ezetimibe	Oral cholesterol-absorption blocker	$9–$30/month generic	15–20%
Lipitor / generic atorvastatin	High-intensity statin	$6–$15/month generic	40–55%
Crestor / generic rosuvastatin	High-intensity statin	$8–$20/month generic	45–55%

Two things jump out of that table.

First, the cheapest options aren't weak. High-intensity atorvastatin or rosuvastatin can lower LDL by roughly half for under $20 a month. Adding generic ezetimibe on top gets you another 15% to 20% for pocket change. A maximally dosed statin plus ezetimibe — call it $30 a month — closes a lot of the gap to a PCSK9 inhibitor.

Second, the expensive orals are a poor deal on price alone. Nexletol costs about as much as Repatha's direct-pay price while lowering LDL a third as much. It exists for people who genuinely cannot take statins, not as a budget alternative.

None of this is a reason to change your own prescription. People end up on Repatha for real reasons — familial hypercholesterolemia, documented statin intolerance, LDL that stays high on maximum oral therapy, or established cardiovascular disease where every point of LDL matters. But if you've never actually tried a statin-plus-ezetimibe combination at full dose, that's a conversation worth having before you commit to $3,000 to $9,000 a year. If tolerability is what pushed you toward an injectable, our breakdown of Repatha side effects and ezetimibe side effects covers what to expect from each.

Is there a generic or biosimilar version of Repatha?

Not in the United States, and not soon.

Repatha is a biologic, so a conventional generic isn't possible. The equivalent would be a biosimilar version of evolocumab, and the FDA has not approved one. Amgen's regulatory exclusivity on the reference product runs into 2027, and the company holds method-of-use and formulation patents stretching well past that — some as far as 2036. Patent-term extension could push the core composition patent to 2029 or 2030.

Biosimilar candidates are in development, so a US launch will happen eventually. Planning your budget around it before 2028 would be optimistic.

Praluent is in a similar position. Leqvio, approved more recently, has even longer to run.

Ways to actually lower what you pay for Repatha

Ranked by how much they typically save, not by how often they get mentioned:

Compare the direct-to-patient price against everything else. At $239 a month it's currently well below US retail, and it doesn't require insurance approval. Confirm what dose that price covers.

Get on the every-two-weeks schedule if it's clinically appropriate. Twenty-six pens a year instead of thirty-six is the single largest lever most patients have.

Run the numbers through your plan before dismissing it. If you have Part D or you're likely to hit your commercial out-of-pocket maximum this year, insurance may beat any cash price — and cash purchases don't count toward either.

Ask about a 90-day fill. Specialty pharmacies often price three months lower per pen than three separate monthly fills, and it cuts down on shipping and cold-chain handling.

Price the oral backbone separately. Most people on Repatha also take a statin, and sometimes ezetimibe. Those prescriptions don't have to come from the same pharmacy. Cash-pay networks like CanAmerica Plus list brand Crestor at $195.99 for 90 tablets and generic ezetimibe at $57.99 for 100 tablets — worth comparing against your local pharmacy's cash price on each.

Don't let it sit unrefrigerated by accident. Repatha keeps at room temperature for up to 30 days in its original carton, but past that it has to be discarded. At roughly $344 a pen, one spoiled shipment costs more than a month of statins for a decade.

The bottom line

Repatha in 2026 costs between $239 and about $780 a month depending entirely on how you buy it, and the direct-to-patient route is currently the cheapest cash option in the US. Your dosing schedule matters nearly as much as your pharmacy — the monthly 420 mg regimen quietly costs about 38% more per year than the every-two-weeks schedule.

Before your next fill, do two things: confirm which dosing schedule you're on and what it costs annually, and ask your prescriber whether a full-dose statin plus ezetimibe has genuinely been tried. If the answer is yes and your LDL is still high, Repatha is doing real work and it's worth finding the cheapest legitimate route to it.

Frequently asked questions

How much does Repatha cost per month without insurance?

US retail cash prices generally run $625 to $780 per month for two 140 mg pens. Amgen's direct-to-patient program prices it at $239 a month, which is currently the lowest widely available cash price in the US. Prices vary by pharmacy and by dosing schedule, so get a written quote before your first fill.

Why is Repatha so expensive?

It's a biologic — a lab-made monoclonal antibody that costs far more to manufacture than a small-molecule pill — and it has no biosimilar competition in the US. Brand-only biologics hold their price until a competing version launches, which for evolocumab is still years away.

Is there a cheaper alternative to Repatha?

Generic high-intensity statins like atorvastatin and rosuvastatin cost $6 to $20 a month and lower LDL by roughly half. Adding generic ezetimibe for another $9 to $30 a month provides an additional 15% to 20%. Praluent is the closest direct alternative and is priced similarly to Repatha. Any switch needs to go through your prescriber, since these options don't lower LDL by the same amount.

Does Medicare cover Repatha?

Most Part D and Medicare Advantage drug plans include Repatha, typically on a specialty tier with prior authorization. Around three-quarters of Medicare prescriptions for it cost $50 or less per month. Since 2025, Part D also caps your annual out-of-pocket drug spending, which limits worst-case exposure.

When will a Repatha generic or biosimilar be available?

No evolocumab biosimilar has been approved in the US. Reference-product exclusivity runs into 2027 and Amgen holds later patents on formulation and use, so most estimates put a realistic US launch somewhere between 2028 and 2030 depending on how patent litigation resolves.

---

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.